Xeris Biopharma Holdings, Inc. Common Stock (XERS) is a publicly traded Healthcare sector company. As of May 21, 2026, XERS trades at $6.23 with a market cap of $1.04B and a P/E ratio of 88.21. XERS moved +5.07% today. Year to date, XERS is -12.13%; over the trailing twelve months it is +22.64%. Its 52-week range spans $2.69 to $10.08. Analyst consensus is strong buy with an average price target of $12.25. Rallies surfaces XERS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Xeris Biopharma Tops Q4 EPS Estimates, Reports $85.8M Revenue: Xeris Biopharma reported Q4 2025 EPS of $0.06 versus estimates of $0.03 and revenue of $85.8 million slightly below projections. The company’s P/S ratio stands at 3.48, debt-to-equity at 2.76 and it issued optimistic financial guidance for 2026 highlighting growth potential.
| Metric | Value |
|---|---|
| Price | $6.23 |
| Market Cap | $1.04B |
| P/E Ratio | 88.21 |
| EPS | $0.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.08 |
| 52-Week Low | $2.69 |
| Volume | 5 |
| Avg Volume | 0 |
| Revenue (TTM) | $314.85M |
| Net Income | $12.01M |
| Gross Margin | 0.00% |
4 analysts cover XERS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.25.